Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial

An estimated 35,633 major cardiovascular events and 22,117 deaths could be prevented with 50% uptake of semaglutide 2.4 mg weekly over four years.

• In a sample of 216 individuals, corresponding to approximately 4.5 million adults in the U.S., significant cardiovascular health improvements may be achievable with semaglutide.
• Without semaglutide, 356,329 major cardiovascular events and 232,808 deaths from any cause were expected over four years.
• Preventive benefits of semaglutide could be substantial, highlighting its potential role in secondary cardiovascular disease management.
• The findings suggest that increasing access to semaglutide may lead to meaningful reductions in cardiovascular morbidity and mortality.

AI simplified